SAN DIEGO, July 20, 2015 /PRNewswire/ -- Applied Proteomics Inc., a developer of protein-based molecular diagnostics, announced today the appointment of William R. LaRue to the company's Board of Directors. Mr. LaRue has more than 25 years of experience in corporate leadership and growth strategies, including serving as senior vice president and chief financial officer of Cadence Pharmaceuticals, Inc. from June 2006 through its acquisition by Mallinckrodt plc in 2014 for $1.4 billion.
"The team at Applied Proteomics is pioneering novel and innovative approaches where there is unmet clinical need, particularly in diagnosis of cancer," said Mr. LaRue. "It's an exciting time to come on board, as the team heads toward development and launch of commercial tests."
"Bill's strategic and financial experience make him an ideal addition to our board of directors," said Peter Klemm, Ph.D., president and CEO of Applied Proteomics. "We look forward to benefiting from his deep financial knowledge, particularly in the biotechnology space."
During his eight years as senior vice president and chief financial officer at Cadence Pharmaceuticals, Mr. LaRue helped transition the company from clinical development to commercial operations. Mr. LaRue also serves on the board of directors of TRACON Pharmaceuticals, Inc., focused on targeted therapies for cancer and macular degeneration.
Prior to joining Cadence Pharmaceuticals, Mr. LaRue was senior vice president and chief financial officer for Micromet, Inc. (formerly Cancervax Corporation), a biotechnology company focused on the treatment and control of cancer. Mr. LaRue was vice president and treasurer of Safeskin Corporation, a maker of disposable gloves for the health care, high technology and scientific industries, until its acquisition by Kimberly-Clark Corporation.
Mr. LaRue has an MBA and B.S. in business administration from the University of Southern California.
About Applied Proteomics Inc.
Applied Proteomics Inc. is advancing the application of proteomics to the development of diagnostics, companion diagnostics, and personalized medicine applications to power better medical decisions and care. Applied Proteomics has developed a proteomics platform solution to make protein-based biomarker discovery possible as a replicable, industrial application ready to be applied to health diagnostic problems. Applied Proteomics' platform combines improved instrumentation, faster computing and extensive genome annotations with regimented standard operating procedures, extensive quality controls, and documented processes spanning hundreds of steps from sample collection to processing through informatics. Applied Proteomics is currently advancing a blood-based test for use in helping to assess colorectal cancer . Applied Proteomics is headquartered in San Diego.
For more information, please visit http://www.appliedproteomics.com.
SOURCE Applied Proteomics Inc.